Skip to main content
SpringerLink
Log in

Myths, Pearls, and Tips Regarding Sjögren’s Syndrome

  • Chapter
  • First Online:
Sjögren’s Syndrome

  • 1584 Accesses

Abstract

Although SS is among the three most common rheumatologic disorders, there are few double-blind, placebo-controlled studies to rationally guide either topical or systemic therapy. Therefore, we wish to share some of the clinical “myths and pearls” that we have encountered, including the following:

  1. (a)

    Although the diagnostic criteria of SS depend on a positive anti-SS-A/B antibody, there is significant variation among laboratories in the sensitivity and specificity of these tests. SS patients may have other autoantibodies (such as anti-centromere) antibodies and should not be excluded from diagnosis of SS.

  2. (b)

    Many pathologists do not have experience in reading minor salivary gland biopsies. Outside review of biopsies at a center with expertise is frequently required.

  3. (c)

    The severity of symptoms, as assessed by the patient, is strongly influenced by “fibromyalgia” (central pain sensitization), and this may partly explain the poor correlation between objective measurements of glandular (tear/mouth) and extraglandular (neuropathic) symptoms.

  4. (d)

    The key extraglandular concerns among SS patients are lymphoma and central nervous system involvement. Development of cost-effective strategies to screen patients for these relatively uncommon complications is necessary.

  5. (e)

    Oral dryness leads to change in socialization habits, when the patient can no longer eat with friends, family, or business colleagues. Ocular dryness interferes with work efficiently as patients increasingly sit in front of computer screens in low-humidity office buildings. Therapy must recognize that these problems not only are more than an “irritation” to the patient but also strongly influence their quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M, Del Papa N, De Vita S, Epis O, Franceschini F, Gerli R, Govoni M, Bongi SM, Maglione W, Migliaresi S, Montecucco C, Orefice M, Priori R, Tavoni A, Valesini G. Sjogren’s syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007;56:2223–31.

    PubMed  Google Scholar 

  2. Vitali C. Classification criteria for Sjogren’s syndrome. Ann Rheum Dis. 2003;62:94–5; author reply 5.

    PubMed  CAS  Google Scholar 

  3. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40:1601–11.

    PubMed  CAS  Google Scholar 

  4. Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Rothfield NF, Smeenk R, Takasaki Y, van Venrooij WJ, Wiik A, Wilson M, Koziol JA. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum. 1999;42:455–64.

    PubMed  CAS  Google Scholar 

  5. Ramos-Casals M, Nardi N, Brito-Zeron P, Aguilo S, Gil V, Delgado G, Bove A, Font J. Atypical autoantibodies in patients with primary Sjogren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum. 2006;35:312–21.

    PubMed  CAS  Google Scholar 

  6. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, Calvo-Alen J, Jimenez-Alonso J, Mico ML, Beltran J, Belenguer R, Pallares L. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008;87:210–19.

    CAS  Google Scholar 

  7. Lopez-Hoyos M, Rodriguez-Valverde V, Martinez-Taboada V. Performance of antinuclear antibody connective tissue disease screen. Ann NY Acad Sci. 2007;1109:322–9.

    PubMed  Google Scholar 

  8. Liberatore G, Jackson-Lewis V, Vukosavic S, Mandir A, Vila M, McAuliffe W, Dawson V, Dawson T, Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 1999;5:1403–9.

    PubMed  CAS  Google Scholar 

  9. Arnett F. Histocompatibility typing in the rheumatic diseases: diagnostic and prognostic implications. Med Clin NA. 20:371–87.

    Google Scholar 

  10. Arnett FC, Hamilton RG, Reveille JD, Bias WB, Harley JB, Reichlin M. Genetic studies of Ro (SS-A) and La (SS-B) autoantibodies in families with systemic lupus erythematosus and primary Sjogren’s syndrome. Arthritis Rheum. 1989;32:413–9.

    PubMed  CAS  Google Scholar 

  11. Eracleous E, Kallis S, Tziakouri C, Blease S, Gourtsoyiannis N. Sonography, CT, CT sialography, MRI and MRI sialography in investigation of the facial nerve and the differentiation between deep and superficial parotid lesions. Neuroradiology 1997;39:506–11.

    PubMed  CAS  Google Scholar 

  12. Makula E, Pokorny G, Kiss M, Voros E, Kovacs L, Kovacs A, Csernay L, Palko A. The place of magnetic resonance and ultrasonographic examinations of the parotid gland in the diagnosis and follow-up of primary Sjogren’s syndrome. Rheumatology (Oxford) 2000;39:97–104.

    CAS  Google Scholar 

  13. Hakansson U, Jacobsson L, Lilja B, Manthorpe R, Henriksson V. Salivary gland scintigraphy in subjects with and without symptoms of dry mouth and/or eyes, and in patients with primary Sjogren’s syndrome. Scand J Rheumatol. 1994;23:326–33.

    PubMed  CAS  Google Scholar 

  14. Helman J, Turner RJ, Fox PC, Baum BJ. 99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl− co-transport system. J Clin Invest. 1987;79:1310–3.

    PubMed  CAS  Google Scholar 

  15. Kohn WG, Ship JA, Atkinson JC, Patton LL, Fox PC. Salivary gland 99mTc-scintigraphy: a grading scale and correlation with major salivary gland flow rates. J Oral Pathol Med. 1992;21:70–4.

    PubMed  CAS  Google Scholar 

  16. Burlage FR, Pijpe J, Coppes RP, Hemels ME, Meertens H, Canrinus A, Vissink A. Variability of flow rate when collecting stimulated human parotid saliva. Eur J Oral Sci. 2005;113:386–90.

    PubMed  Google Scholar 

  17. Rosas J, Ramos-Casals M, Ena J, Garcia-Carrasco M, Verdu J, Cervera R, Font J, Caballero O, Ingelmo M, Pascual E. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjogren’s syndrome. Correlation with clinical, immunological and histological features. Rheumatology (Oxford) 2002;41:670–5.

    CAS  Google Scholar 

  18. Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum. 1985;28:1128–32.

    PubMed  CAS  Google Scholar 

  19. Stevens WJ, Swartele FE, Empsten FA, De Clerck LS. Use of the Saxon test as a measure of saliva production in a reference population of schoolchildren. Am J Dis Child. 1990;144:570–1.

    PubMed  CAS  Google Scholar 

  20. Isenberg DA. Systemic lupus erythematosus and Sjogren’s syndrome: historical perspective and ongoing concerns. Arthritis Rheum. 2004;50:681–3.

    PubMed  Google Scholar 

  21. Diamond B. Systemic lupus erythematosus and Sjogren’s syndrome. Curr Opin Rheumatol. 2007;19:405.

    PubMed  Google Scholar 

  22. Garcia-Carrasco M, Cervera R, Rosas J, Ramos-Casals M, Morla RM, Siso A, Jimenez S, Pallares L, Font J, Ingelmo M. Primary Sjogren’s syndrome in the elderly: clinical and immunological characteristics. Lupus 1999;8:20–3.

    PubMed  CAS  Google Scholar 

  23. Isenberg D. Sjogren’s syndrome – a house of cards. Clin Rheumatol. 1995;14 Suppl 1:8–10.

    PubMed  Google Scholar 

  24. Moutsopoulos HM. Sjogren’s syndrome or autoimmune epithelitis? Clin Rev Allergy Immunol. 2007;32:199–200.

    PubMed  CAS  Google Scholar 

  25. Tsonis IA, Avrameas S, Moutsopoulos HM. Autoimmunity and pathophysiology. J Autoimmun. 2007;29:203–5.

    PubMed  CAS  Google Scholar 

  26. Fox RI. Sjogren’s syndrome. Lancet 2005;366:321–31.

    PubMed  CAS  Google Scholar 

  27. Macri A, Pflugfelder S. Correlation of the Schirmer 1 and fluorescein clearance tests with the severity of corneal epithelial and eyelid disease. Arch Ophthalmol. 2000;118:1632–8.

    PubMed  CAS  Google Scholar 

  28. Spiteri A, Mitra M, Menon G, Casini A, Adams D, Ricketts C, Hickling P, Fuller ET, Fuller JR. Tear lipid layer thickness and ocular comfort with a novel device in dry eye patients with and without Sjogren’s syndrome. J Fr Ophtalmol. 2007;30:357–64.

    PubMed  CAS  Google Scholar 

  29. Pflugfelder SC, Liu Z, Monroy D, Li DQ, Carvajal ME, Price-Schiavi SA, Idris N, Solomon A, Perez A, Carraway KL. Detection of sialomucin complex (MUC4) in human ocular surface epithelium and tear fluid. Invest Ophthalmol Vis Sci. 2000;41:1316–26.

    PubMed  CAS  Google Scholar 

  30. Afonso AA, Monroy D, Stern ME, Feuer WJ, Tseng SC, Pflugfelder SC. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. Ophthalmology 1999;106:803–10.

    PubMed  CAS  Google Scholar 

  31. Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, Dua HS, Hom M, Karpecki PM, Laibson PR, Lemp MA, Meisler DM, Castillo JM, O’Brien T P, Pflugfelder SC, Rolando M, Schein OD, Seitz B, Tseng SC, Setten GV, Wilson SE, Yiu SC. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006;25:900–7.

    PubMed  Google Scholar 

  32. de Paiva CS, Pflugfelder SC. Tear clearance implications for ocular surface health. Exp Eye Res. 2004;78:395–7.

    PubMed  Google Scholar 

  33. De Paiva CS, Villarreal AL, Corrales RM, Rahman HT, Chang VY, Farley WJ, Stern ME, Niederkorn JY, Li DQ, Pflugfelder SC. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Invest Ophthalmol Vis Sci. 2007;48:2553–60.

    PubMed  Google Scholar 

  34. Luo L, Li DQ, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens. 2005;31:186–93.

    PubMed  Google Scholar 

  35. Pflugfelder SC, Huang AJ, Feuer W, Chuchovski PT, Pereira IC, Tseng SC. Conjunctival cytologic features of primary Sjogren’s syndrome. Ophthalmology 1990;97:985–91.

    PubMed  CAS  Google Scholar 

  36. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren’s syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19:201–11.

    PubMed  CAS  Google Scholar 

  37. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 2000;19:644–9.

    PubMed  CAS  Google Scholar 

  38. Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea 2007;26:431–7.

    PubMed  Google Scholar 

  39. Goto E, Matsumoto Y, Kamoi M, Endo K, Ishida R, Dogru M, Kaido M, Kojima T, Tsubota K. Tear evaporation rates in Sjogren syndrome and non-Sjogren dry eye patients. Am J Ophthalmol. 2007;144:81–5.

    PubMed  Google Scholar 

  40. Atkinson JC, Fox PC. Sjogren’s syndrome: oral and dental considerations. J Am Dent Assoc. 1993;124:74–6.

    PubMed  CAS  Google Scholar 

  41. Fox PC, Mandel ID. Effects of pilocarpine on salivary flow in patients with Sjogren’s syndrome [letter; comment]. Oral Surg Oral Med Oral Pathol. 1992;74:315–8.

    PubMed  CAS  Google Scholar 

  42. Wolff A, Fox PC, Ship JA, Atkinson JC, Macynski AA, Baum BJ. Oral mucosal status and major salivary gland function. Oral Surg Oral Med Oral Pathol. 1990;70:49–54.

    PubMed  CAS  Google Scholar 

  43. Wu AJ, Fox PC. Sjogren’s syndrome. Semin Dermatol. 1994;13:138–43.

    PubMed  CAS  Google Scholar 

  44. Daniels S. We all need to know about Sjogren’s syndrome. Nurs Times. 2007;103:15.

    Google Scholar 

  45. Hershkovich O, Shafat I, Nagler RM. Age-related changes in salivary antioxidant profile: possible implications for oral cancer. J Gerontol A Biol Sci Med Sci. 2007;62:361–6.

    PubMed  Google Scholar 

  46. Nagler RM. Salivary glands and the aging process: mechanistic aspects, health-status and medicinal-efficacy monitoring. Biogerontology 2004;5:223–33.

    PubMed  CAS  Google Scholar 

  47. Abraham CM, al-Hashimi I, Haghighat N. Evaluation of the levels of oral Candida in patients with Sjogren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86:65–8.

    PubMed  CAS  Google Scholar 

  48. Almstahl A, Kroneld U, Tarkowski A, Wikstrom M. Oral microbial flora in Sjogren’s syndrome. J Rheumatol. 1999;26:110–4.

    PubMed  CAS  Google Scholar 

  49. Rhodus NL, Michalowicz BS. Periodontal status and sulcular Candida albicans colonization in patients with primary Sjogren’s syndrome. Quintessence Int. 2005;36:228–33.

    PubMed  Google Scholar 

  50. Sweet SP, Denbury AN, Challacombe SJ. Salivary calprotectin levels are raised in patients with oral candidiasis or Sjogren’s syndrome but decreased by HIV infection. Oral Microbiol Immunol. 2001;16:119–23.

    PubMed  CAS  Google Scholar 

  51. Tsai H, Bobek LA. Human salivary histatins: promising anti-fungal therapeutic agents. Crit Rev Oral Biol Med. 1998;9:480–97.

    PubMed  CAS  Google Scholar 

  52. Peluso G, De Santis M, Inzitari R, Fanali C, Cabras T, Messana I, Castagnola M, Ferraccioli GF. Proteomic study of salivary peptides and proteins in patients with Sjogren’s syndrome before and after pilocarpine treatment. Arthritis Rheum. 2007;56:2216–22.

    PubMed  CAS  Google Scholar 

  53. Nagler RM, Hershkovich O. Relationships between age, drugs, oral sensorial complaints and salivary profile. Arch Oral Biol. 2005;50:7–16.

    PubMed  Google Scholar 

  54. Daniels TE, Fox PC. Salivary and oral components of Sjogren’s syndrome. Rheum Dis Clin North Am. 1992;18:571–89.

    PubMed  CAS  Google Scholar 

  55. Daniels TE, Wu AJ. Xerostomia – clinical evaluation and treatment in general practice. J Calif Dent Assoc. 2000;28:933–41.

    PubMed  CAS  Google Scholar 

  56. Maltsman-Tseikhin A, Moricca P, Niv D. Burning mouth syndrome: will better understanding yield better management? Pain Pract. 2007;7:151–62.

    PubMed  Google Scholar 

  57. Patton L, Siegel M, Benoliel R, De Laat A. Management of burning mouth syndrome: systematic review and management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2007;S39:1–13.

    Google Scholar 

  58. Belafsky PC, Postma GN. The laryngeal and esophageal manifestations of Sjogren’s syndrome. Curr Rheumatol Rep. 2003;5:297–303.

    PubMed  Google Scholar 

  59. Postma GN, Belafsky PC, Aviv JE, Koufman JA. Laryngopharyngeal reflux testing. Ear Nose Throat J. 2002;81:14–8.

    PubMed  Google Scholar 

  60. Jara LJ, Navarro C, Brito-Zeron Mdel P, Garcia-Carrasco M, Escarcega RO, Ramos-Casals M. Thyroid disease in Sjogren’s syndrome. Clin Rheumatol. 2007;26:1601–6.

    PubMed  Google Scholar 

  61. D’Arbonneau F, Ansart S, Le Berre R, Dueymes M, Youinou P, Pennec YL. Thyroid dysfunction in primary Sjogren’s syndrome: a long-term followup study. Arthritis Rheum. 2003;49:804–9.

    PubMed  Google Scholar 

  62. Fox PC. An Autoimmune Exocrinopathy. Ann NY Acad Sci. 2007;1098:15–21.

    Google Scholar 

  63. Stojanovich L, Milovanovich B, de Luka SR, Popovich-Kuzmanovich D, Bisenich V, Djukanovich B, Randjelovich T, Krotin M. Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjogren syndrome and other autoimmune diseases. Lupus. 2007;16:181–5.

    PubMed  CAS  Google Scholar 

  64. Mandl T, Wollmer P, Manthorpe R, Jacobsson LT. Autonomic and orthostatic dysfunction in primary Sjogren’s syndrome. J Rheumatol. 2007;34:1869–74.

    PubMed  Google Scholar 

  65. Cervera R, Font J, Ramos-Casals M, Garcia-Carrasco M, Rosas J, Morla RM, Munoz FJ, Artigues A, Pallares L, Ingelmo M. Primary Sjogren’s syndrome in men: clinical and immunological characteristics. Lupus. 2000;9:61–4.

    PubMed  CAS  Google Scholar 

  66. Launay D, Hachulla E, Hatron PY, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007;86:299–315.

    Google Scholar 

  67. Ramos-Casals M, Anaya J, GarcÌa-Carrasco M, Rosas J, BovÈ A, Claver G, Diaz L, Herrero C, Font J. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine 2004;83:96.

    PubMed  Google Scholar 

  68. Ramos-Casals M, Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol. 2005;17:447–55.

    PubMed  Google Scholar 

  69. Ramos-Casals M, Font J. Primary Sjogren’s syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford) 2005.

    Google Scholar 

  70. Ramos-Casals M, Jara LJ, Medina F, Rosas J, Calvo-Alen J, Mana J, Anaya JM, Font J. Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. J Intern Med. 2005;257:549–57.

    PubMed  CAS  Google Scholar 

  71. Boki KA, Ioannidis JP, Segas JV, Maragkoudakis PV, Petrou D, Adamopoulos GK, Moutsopoulos HM. How significant is sensorineural hearing loss in primary Sjogren’s syndrome? An individually matched case–control study. J Rheumatol. 2001;28:798–801.

    PubMed  CAS  Google Scholar 

  72. Ramos-Casals M, Tzioufas A, Font J. Primary Sjogren’s syndrome: new clinical and therapeutic concepts. Br Med J. 2005;64:347.

    CAS  Google Scholar 

  73. Walker J, Gordon T, Lester S, Downie-Doyle S, McEvoy D, Pile K, Waterman S, Rischmueller M. Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjögren’s syndrome. J Rheumatol. 2003;30:2406.

    PubMed  Google Scholar 

  74. Leppilahti M, Tammela TL, Huhtala H, Kiilholma P, Leppilahti K, Auvinen A. Interstitial cystitis-like urinary symptoms among patients with Sjogren’s syndrome: a population-based study in Finland. Am J Med. 2003;115:62–5.

    PubMed  Google Scholar 

  75. Rosamilia A. Painful bladder syndrome/interstitial cystitis. Best Pract Res Clin Obstet Gynaecol. 2005;19:843–59.

    PubMed  Google Scholar 

  76. Lindvall B, Bengtsson A, Ernerudh J, Eriksson P. Subclinical myositis is common in primary Sjögren’s syndrome and is not related to muscle pain. J Rheumatol. 2002;29:717.

    PubMed  Google Scholar 

  77. Silverman B, Brown L, Bright R, Kaczmarek R, Arrowsmith-Lowe J, Kessler D. Reported complications of silicone gel breast implants: an epidemiologic review. Ann Int Med. 1996;124:744–56.

    PubMed  CAS  Google Scholar 

  78. Fox RI, Stern M. Sjogren’s syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl. 2002;3–13.

    Google Scholar 

  79. Konttinen YT, Hukkanen M, Kemppinen P, Segerberg M, et al. Peptide-containing nerves in labial salivary glands in Sjögren’s syndrome. Arthritis Rheum. 1992;35:815–20.

    PubMed  CAS  Google Scholar 

  80. Beroukas D, Goodfellow R, Hiscock J, Jonsson R, Gordon TP, Waterman SA. Up-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjogren’s syndrome. Lab Invest. 2002;82:203–10.

    PubMed  CAS  Google Scholar 

  81. Beroukas D, Hiscock J, Gannon BJ, Jonsson R, Gordon TP, Waterman SA. Selective down-regulation of aquaporin-1 in salivary glands in primary Sjogren’s syndrome. Lab Invest. 2002;82:1547–52.

    PubMed  CAS  Google Scholar 

  82. Beroukas D, Hiscock J, Jonsson R, Waterman SA, Gordon TP. Subcellular distribution of aquaporin 5 in salivary glands in primary Sjogren’s syndrome. Lancet 2001;358:1875–6.

    PubMed  CAS  Google Scholar 

  83. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjogren’s syndrome. Clin Immunol. 2001;101:249–63.

    PubMed  CAS  Google Scholar 

  84. Hurst S, Collins S. Interleukin-1 beta modulation of norepinephrine release from rat myenteric nerves. Am J Physiol. 1993;264:G30–G5.

    PubMed  CAS  Google Scholar 

  85. Hurst SM, Collins SM. Mechanism underlying tumor necrosis factor-alpha suppression of norepinephrine release from rat myenteric plexus. Am J Physiol. 1994;266:G1123–9.

    PubMed  CAS  Google Scholar 

  86. Baum BJ, Dai Y, Hiramatsu Y, Horn VJ, Ambudkar IS. Signaling mechanisms that regulate saliva formation. Crit Rev Oral Biol Med. 1993;4:379–84.

    PubMed  CAS  Google Scholar 

  87. Bacman S, Sterin-Borda L, Camusso JJ, Arana R, Hubscher O, Borda E. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren’s syndrome. Clin Exp Immunol. 1996;104:454–9.

    PubMed  CAS  Google Scholar 

  88. Bacman SR, Berra A, Sterin-Borda L, Borda ES. Human primary Sjogren’s syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr Eye Res. 1998;17:1135–42.

    PubMed  CAS  Google Scholar 

  89. Wolkoff P, Nojgaard JK, Franck C, Skov P. The modern office environment desiccates the eyes? Indoor Air 2006;16:258–65.

    PubMed  CAS  Google Scholar 

  90. Nakamori K, Odawara M, Nakajima T, Mizutani T, Tsubota K. Blinking is controlled primarily by ocular surface conditions. Am J Ophthalmol. 1997;124:24–30.

    PubMed  CAS  Google Scholar 

  91. Tsubota K. Tear dynamics and dry eye. Prog Retin Eye Res. 1998;17:565–96.

    PubMed  CAS  Google Scholar 

  92. Hu S, Loo JA, Wong DT. Human saliva proteome analysis and disease biomarker discovery. Expert Rev Proteomics. 2007;4:531–8.

    PubMed  CAS  Google Scholar 

  93. Hu S, Loo JA, Wong DT. Human saliva proteome analysis. Ann NY Acad Sci. 2007;1098:323–9.

    PubMed  CAS  Google Scholar 

  94. Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, Zhou H, Henry S, Vissink A, Pijpe J, Kallenberg C, Elashoff D, Loo JA, Wong DT. Salivary proteomic and genomic biomarkers for primary Sjogren’s syndrome. Arthritis Rheum. 2007;56:3588–600.

    PubMed  CAS  Google Scholar 

  95. Giusti L, Baldini C, Bazzichi L, Ciregia F, Tonazzini I, Mascia G, Giannaccini G, Bombardieri S, Lucacchini A. Proteome analysis of whole saliva: a new tool for rheumatic diseases – the example of Sjogren’s syndrome. Proteomics 2007;7:1634–43.

    PubMed  CAS  Google Scholar 

  96. Laine M, Porola P, Udby L, Kjeldsen L, Cowland JB, Borregaard N, Hietanen J, Stahle M, Pihakari A, Konttinen YT. Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 levels in Sjogren’s syndrome. Arthritis Rheum. 2007;56:2575–84.

    PubMed  CAS  Google Scholar 

  97. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren’s syndrome: a pilot study. Arthritis Rheum. 2001;44:2371–5.

    PubMed  CAS  Google Scholar 

  98. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puechal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J. Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–6.

    PubMed  CAS  Google Scholar 

  99. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–5.

    PubMed  CAS  Google Scholar 

  100. Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren’s syndrome: a pilot study. J Rheumatol. 2004;31:96–101.

    PubMed  CAS  Google Scholar 

  101. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol). 2007;19:83–6.

    CAS  Google Scholar 

  102. Kawakami A, Nakashima K, Tamai M, Nakamura H, Iwanaga N, Fujikawa K, Aramaki T, Arima K, Iwamoto N, Ichinose K, Kamachi M, Ida H, Origuchi T, Eguchi K. Toll-like receptor in salivary glands from patients with Sjogren’s syndrome: functional analysis by human salivary gland cell line. J Rheumatol. 2007;34:1019–26.

    PubMed  CAS  Google Scholar 

  103. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren’s syndrome. Autoimmun Rev. 2010;9:A305–A10.

    PubMed  Google Scholar 

  104. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, Brokstad K, Jonsson R, Jonsson MV. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren’s syndrome. Ann Rheum Dis. 2011;70:1363–70.

    PubMed  Google Scholar 

  105. Mariette X, Gottenberg JE. Pathogenesis of Sjogren’s syndrome and therapeutic consequences. Curr Opin Rheumatol. 2010;22:471.

    PubMed  CAS  Google Scholar 

  106. Atalar K, Afzali B, Lams B, Tungekar MF, Goldsmith DJ. Falls, hypokalaemia, and a dry mouth. Lancet 2007;370:192.

    PubMed  Google Scholar 

  107. Chan K. Chinese medicinal materials and their interface with Western medical concepts. J Ethnopharmacol. 2005;96:1–18.

    PubMed  Google Scholar 

  108. Chang YH, Lin HJ, Li WC. Clinical evaluation of the traditional Chinese prescription Chi-Ju-Di-Huang-Wan for dry eye. Phytother Res. 2005;19:349–54.

    PubMed  Google Scholar 

  109. Ernst E. Harmless herbs? A review of the recent literature. Am J Med. 1998;104:170–8.

    PubMed  CAS  Google Scholar 

  110. Ernst E. Herb–drug interactions: potentially important but woefully under-researched. Eur J Clin Pharmacol. 2000;56:523–4.

    PubMed  CAS  Google Scholar 

  111. Nishimagi E, Kawaguchi Y, Terai C, Kajiyama H, Hara M, Kamatani N. Progressive interstitial renal fibrosis due to Chinese herbs in a patient with calcinosis Raynaud esophageal sclerodactyly telangiectasia (CREST) syndrome. Intern Med. 2001;40:1059–63.

    PubMed  CAS  Google Scholar 

  112. Liang L, Zhang M, Zou W, Liu Z. Aggravated dry eye after laser in situ keratomileusis in patients with Sjogren syndrome. Cornea 2008;27:120–3.

    PubMed  Google Scholar 

  113. Lekhanont K, Leyngold IM, Suwan-Apichon O, Rangsin R, Chuck RS. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. Cornea 2007;26:84–9.

    PubMed  Google Scholar 

  114. Mellgren SI, Goransson LG, Omdal R. Primary Sjogren’s syndrome associated neuropathy. Can J Neurol Sci. 2007;34:280–7.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Clinic, Scripps Memorial Hospital and Research Foundation, La Jolla, CA, USA

    Robert I. Fox

  2. Sjögren Syndrome Research Group (AGAUR), Hospital Clinic, Barcelona, Spain

    Manuel Ramos-Casals

  3. Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA

    John H. Stone

Authors
  1. Robert I. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manuel Ramos-Casals
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John H. Stone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert I. Fox .

Editor information

Editors and Affiliations

  1. Research Foundation, Rheumatology Clinic, Scripps Memorial Hospital &, Caminito Sinnecock 6565, La Jolla, 92037, California, USA

    Robert I. Fox

  2. Research Foundation, Rheumatology Clinic, Scripps Memorial Hospital &, Caminito Sinnecock 6565, La Jolla, 92037, California, USA

    Carla M. Fox

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Fox, R.I., Ramos-Casals, M., Stone, J.H. (2011). Myths, Pearls, and Tips Regarding Sjögren’s Syndrome. In: Fox, R., Fox, C. (eds) Sjögren’s Syndrome. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-957-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-957-4_3

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60327-956-7

  • Online ISBN: 978-1-60327-957-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation